This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ventas, Inc. is a healthcare real estate investment trust (REIT) that is primarily engaged in acquisition and ownership of senior housing, R&I and healthcare properties, and leasing them to unaffiliated tenants or operating them through independent third-party managers. Ventas offers MOB management, leasing, marketing, facility development and advisory services to well-rated hospitals and health systems throughout the United States through its ownership interest in PMB Real Estate Services LLC and the company’s subsidiary, Lillibridge Healthcare Services, Inc. It also makes secured and non-mortgage loans and other investments relating to senior housing and healthcare properties or operators.
Welltower (WELL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Welltower's (WELL) Q2 earnings are expected to have benefited from the rise in the senior citizen population and this age cohort's high healthcare expenditure. However, high interest expenses remain a concern.
Digital Realty (DLR) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Digital Realty's (DLR) Q2 earnings are likely to have been aided by solid data center demand and acceleration in digital transformation strategies. However, high interest expenses may have been a concern.
Alexandria (ARE) Q2 AFFO Beats Estimates, Revenues Miss
by Zacks Equity Research
Alexandria's (ARE) Q2 AFFO outshines estimates. Results reflect decent leasing activity and higher rental rates.
What's in the Cards for Healthpeak (DOC) This Earnings Season?
by Zacks Equity Research
While Healthpeak's (DOC) Q2 earnings are likely to have benefited from the healthy demand for lab real estate assets, high interest expenses raise concern.
Here's Why You Should Retain Ventas (VTR) in Your Portfolio
by Zacks Equity Research
Ventas (VTR) is poised to benefit by leveraging the rise in the aging population, growing outpatient visit trends and a healthy balance sheet. However, higher competition and interest rates are headwinds.
Ventas (VTR) Hits 52-Week High: Will the Stock Trend Higher?
by Zacks Equity Research
Ventas (VTR) is expected to continue to benefiting from a favorable senior housing operating portfolio and outpatient visit trends.
Ventas (VTR) Stock Rises 11.4% in Three Months: Here's How
by Zacks Equity Research
Ventas (VTR) is poised to gain from a favorable demand in senior housing, backed by an expected rise in senior citizens' population despite the high interest rates environment.
Ventas (VTR) Up 6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ventas (VTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ventas (VTR) Sees Occupancy Growth in 2024 on Strong Demand
by Zacks Equity Research
Ventas' (VTR) properties continue to expect occupancy growth in 2024, backed by strong demand.
What's in the Cards for Medical Properties (MPW) in Q1 Earnings?
by Zacks Equity Research
While Medical Properties' (MPW) Q1 earnings are likely to have benefited from the favorable healthcare industry trends, the high interest rate environment may have hurt it.
OUTFRONT Media (OUT) Q1 AFFO Meets Estimates, Revenues Up Y/Y
by Zacks Equity Research
OUTFRONT Media (OUT) Q1 2024 results reflect a rise in billboard revenues. However, higher operating expenses and interest expense pose concerns.
Digital Realty's (DLR) Q1 FFO Beat Estimates, Revenues Lag
by Zacks Equity Research
Digital Realty's (DLR) Q1 FFO per share outshine estimates. However, elevated operating expenses hurt the results to some extent.
Lamar (LAMR) Stock Rises on Q1 AFFO Beat, Revenues Rise Y/Y
by Zacks Equity Research
Lamar's (LAMR) first-quarter 2024 results reflect strong local sales and year-over-year top-line growth. However, the company experiences a surge in interest expenses.
Ventas (VTR) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Ventas (VTR) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ventas (VTR) Q1 FFO Beats Estimates on Higher Same-Store NOI
by Zacks Equity Research
Ventas' (VTR) Q1 results outshine estimates on better-than-anticipated revenues. The same-store NOI improves year over year on strong performance.
Host Hotels' (HST) Q1 AFFO Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Host Hotels (HST) posts better-than-expected Q1 results on higher revenues aided by improvements in group and contract business. It has also raised its 2024 AFFO per share outlook.
Exploring Analyst Estimates for Ventas (VTR) Q1 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Ventas (VTR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
What's in the Offing for Ventas (VTR) This Earnings Season?
by Zacks Equity Research
Favorable SHOP operating trends, healthy demand for life-science real estate assets and accretive investments are likely to have benefited Ventas' (VTR) Q1 earnings.
Alexandria (ARE) Beats Q1 AFFO Estimates, Narrows '24 Guidance
by Zacks Equity Research
Alexandria's (ARE) Q1 results reflect healthy leasing activity and rental rate growth.
SL Green's (SLG) Q1 FFO Beat Estimates, '24 FFO View Raised
by Zacks Equity Research
SL Green's (SLG) Q1 FFO outshines estimates. However, rental revenues and the occupancy in Manhattan's same-store office portfolio fall year over year.
Crown Castle's (CCI) Q1 AFFO Beat, Site-Rental Revenues Fall
by Zacks Equity Research
Crown Castle's (CCI) Q1 earnings outshine estimates. Site rental revenues fall year over year, hurting the top line. However, a fall in operating expenses supported the results to some extent.
Crown Castle's (CCI) Q1 AFFO & Revenues Surpass Estimates
by Zacks Equity Research
Crown Castle's (CCI) Q1 results outshine estimates on better-than-anticipated revenues. However, high interest expense is a concern. It has maintained its 2024 outlook.
Is it Wise to Retain Ventas (VTR) Stock in Your Portfolio?
by Zacks Equity Research
A favorable demand in senior housing, backed by an expected rise in senior citizens' population is likely to support Ventas (VTR). However, dependence on a few tenants and high interest rates are woes.
Ventas (VTR) Sees Strong Demand & Occupancy Growth in 2024
by Zacks Equity Research
Ventas' (VTR) properties are likely to witness an acceleration of occupancy in 2024, backed by strong demand.
Jones Lang's (JLL) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
The continued strength of its resilient lines of business supports Jones Lang's (JLL) Q4 earnings. However, poor transaction-based businesses' performance affected the results to some extent.